Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharvaris
Biotech
FDA lifts remaining hold on Pharvaris’ HAE drug
The preventative oral med for hereditary angioedema has had its remaining hold lifted weeks after the treatment proved its worth in a phase 2 study.
James Waldron
Jan 22, 2024 7:32am
Pharvaris oral hereditary angioedema med cuts attacks in phase 2
Dec 6, 2023 10:18am
Pharvaris runs tox test to reverse clinical hold for HAE asset
Jan 9, 2023 10:42am
Ex-Pfizer R&D head Abraham joins Vividion—Chutes & Ladders
Feb 14, 2020 9:30am
Pharvaris nabs Shire exec as new CMO
Feb 7, 2020 9:22am
